<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1401256604
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2008
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        IMMUNATE S-D 1000 I.U. POWDER FOR INJ
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HUMAN COAGULATION FACTOR VIII,HUMAN VON WILLEBRAND FACTOR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1000,750
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Parenteral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1627
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA MANUFACTURING AUSTRIA AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA MANUFACTURING AUSTRIA AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Takeda Manufacturing AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B02BD02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Immunate is</strong></p><p>Immunate is a coagulation factor VIII / von Willebrand factor complex made from human plasma. The coagulation factor VIII in Immunate replaces the factor VIII which is lacking or is not functioning properly in haemophilia A. Haemophilia A is a sex-linked, hereditary blood coagulation defect due to reduced factor VIII levels. This results in severe bleeding in joints, muscles and inner organs, either spontaneously or as a consequence of accidental or surgical traumata. The administration of Immunate temporarily corrects the factor VIII deficiency and reduces the bleeding tendency.</p><p>In addition to its role as a factor VIII protecting protein, von Willebrand factor (VWF) mediates platelet adhesion to sites of vascular injury and plays a role in platelet aggregation.</p><p>&nbsp;</p><p><strong>What Immunate is used for</strong></p><p>Immunate is used for the treatment and prevention of bleeding in congenital (haemophilia A) or acquired factor VIII deficiency.</p><p>Immunate is also used for the treatment of bleeding in patients with von Willebrand&rsquo;s disease with factor VIII deficiency, if no specific preparation effective against von Willebrand&rsquo;s disease is available, and when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Immunate</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to human coagulation factor VIII or any of the other ingredients of this medicine (listed in section 6). &nbsp;If you are unsure about this, ask your doctor.</p><p><strong>Warnings and precautions</strong></p><p><u>When allergic reactions occur:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is a rare chance that you may experience an anaphylactic reaction (a severe, sudden allergic reaction) to Immunate. You should be aware of the early signs of allergic reactions such as flush, rash, hives, wheals, generalised itching, swelling of lips, eyelid and tongue, dyspnoea, wheezing, chest pain, tightness in the chest, general feeling of being unwell, dizziness, faster heart beat and low blood pressure. These symptoms can constitute an early symptom of an anaphylactic shock, manifestations of which may additionally include extreme dizziness, loss of consciousness, and extreme difficulty in breathing.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If any of these symptoms occur, <u>stop the injection/infusion immediately and contact your doctor</u>. Severe symptoms, including difficulty in breathing and (near) fainting, require immediate emergency treatment.</p><p><u>When monitoring is required:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may wish to carry out tests to ensure that your current dose is sufficient to reach and maintain adequate factor VIII or von Willebrand levels.</p><p><u>When bleeding is still occuring:</u></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The formation of inhibitors (antibodies) is a known complication that can occur during treatment with all Factor VIII medicines. These inhibitors, especially at high levels, stop the treatment working properly and you or your child will be monitored carefully for the development of these inhibitors. If you or your child&acute;s bleeding is not being controlled with Immunate, <u>tell</u><u> your doctor</u> <u>immediately</u>.</p><p>If you have von Willebrand&rsquo;s disease, especially type 3, you may develop neutralizing antibodies &nbsp;(inhibitors) to von Willebrand factor. Your doctor may wish to carry out tests to confirm this. Von Willebrand factor inhibitors are antibodies in the blood that block the von Willebrand factor you are using. This makes von Willebrand factor less effective in controlling bleeding.</p><p>When medicines are made from human blood or plasma, certain measures are put in place to prevent infections being passed on to patients. These include careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, the testing of each donation and pools of plasma for signs of virus/infections, and the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses. Despite these measures, when medicines prepared from human blood or plasma are administered, the possibility of passing on infection cannot be totally excluded. This also applies to any unknown or emerging viruses or other types of infections.</p><p>The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus. The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B 19 infection may be serious for pregnant women (fetal infection) and for individuals whose immune system is depressed or who have some types of anaemia (e.g. sickle cell disease or haemolytic anaemia).</p><p>Your doctor may recommend that you consider vaccination against hepatitis A and B if you regularly/repeatedly receive human plasma-derived factor VIII products.</p><p>It is strongly recommended that every time you receive a dose of Immunate the name and batch number of the medicine are recorded in order to maintain a record of the batches used.</p><p>Immunate contains blood group isoagglutinins (anti-A and anti-B). If you have blood group A, B, or AB, haemolysis may occur following repetitive administration at short intervals or following administration of very large doses.</p><p><strong>Children</strong></p><p>The product should be used with caution in children less than 6 years of age, who have limited exposure to factor VIII products, as there is limited clinical data available for this patient group.</p><p><strong>Other medicines and Immunate</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>No interactions of Immunate with other medicinal products have been reported.</p><p>Immunate must not be mixed with other medicinal products or solvents, except the enclosed Sterilised Water for Injections, prior to administration as this might impair the efficacy and safety of the product. It is advisable to flush implanted venous access with an appropriate solution, e.g. physiological saline solution, prior to and after infusion of Immunate.</p><p><strong>Immunate with food and drink</strong></p><p>There are no specific recommendations as to when Immunate should be administered with regard to meals.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>There is no experience regarding the use of Immunate during pregnancy, breast-feeding and fertility as haemophilia A is rare in women. Immunate should be used during pregnancy and lactation only if clearly indicated. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>There is no information on the effects of Immunate on the ability to drive and use machines.</p><p><strong>Immunate contains sodium</strong></p><p>This medicine contains 19.6 mg sodium (main component of cooking/table salt) in each vial.&nbsp; This is equivalent to approximately 1% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Your therapy should be under the supervision of a doctor experienced in the treatment of haemostatic disorders.</strong></p><p>Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p><strong>Dosage for prevention of bleeding</strong></p><p>If you are using Immunate to prevent bleeding, <u>your doctor will calculate the dose </u>for you. He/she will do this according to your particular needs. The usual dose will be between 20 to 40 IU factor VIII per kg of body weight, administered at intervals of 2 to 3 days. However, in some cases, especially in younger patients, shorter dose intervals or higher doses may be necessary.</p><p>If you have the impression that the effect of Immunate is insufficient, talk to your doctor.</p><p><strong>Dosage for treatment of bleeding</strong></p><p>If you are receiving Immunate for treatment of bleeding, <u>your doctor will calculate the dose </u>for you. He/she will do this according to your particular needs.</p><p>If you have the impression that the effect of Immunate is insufficient, talk to your doctor.</p><p><strong>Monitoring by your doctor</strong></p><p>Your doctor will perform appropriate laboratory tests to make sure that you have adequate factor VIII levels. This is particularly important if you are having major surgery.</p><p><strong>&nbsp;</strong></p><p><strong>Dosage in von Willebrand&rsquo;s disease</strong></p><p>Your doctor will control haemorrhages following the guidelines given for haemophilia A.</p><p>&nbsp;</p><p><strong>Route and/or method of administration</strong></p><p>Immunate is administered <u>into a vein (intravenously) </u>after preparing the solution with the solvent provided.</p><p>Follow the directions given by your doctor closely.</p><p>For reconstitution use only the administration set provided in the pack because treatment failure can occur as a consequence of human coagulation factor VIII adsorption to the internal surfaces of some infusion equipment.</p><p>Immunate is to be reconstituted immediately before administration. The solution should then be used straight away as it does not contain preservatives.</p><p>&nbsp;</p><p><strong>Reconstitution of the powder to prepare a solution for injections</strong></p><p><strong><em>Use aseptic technique!</em></strong></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warm the unopened vial containing the solvent (sterilised water for injections) to room temperature (maximum 37&deg;C).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove protective caps from the powder vial and solvent vial (fig. A) and cleanse the rubber stoppers of both.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place and press the undulated rim of the transfer set onto the solvent vial (fig. B).</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove protective covering from the other end of the transfer set taking care not to touch the exposed end.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Invert the transfer set with the attached solvent vial over the powder vial and insert the free needle through the rubber stopper of the powder vial (fig. C). The solvent will be drawn into the powder vial by vacuum.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After approximately one minute, disconnect the two vials by removing the transfer set with the attached solvent vial from the powder vial (fig. D). Since the preparation dissolves easily, only gently - if at all - agitate the concentrate vial. DO NOT SHAKE THE CONTENTS OF THE VIAL. DO NOT INVERT THE POWDER VIAL UNTIL READY TO WITHDRAW CONTENTS.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After reconstitution, the prepared solution should be inspected visually for particulate matter and discoloration prior to administration. The solution should be clear to slightly opalescent. However, even when the reconstitution procedure is strictly followed, a few small particles may occasionally be visible. The enclosed filter set will remove particles and the labeled potency will not be reduced. Solutions that are turbid or have deposits are to be discarded. The ready-to-use solution must not be put back into the refrigerator.</p><p>&nbsp;</p><p><strong>Administration</strong></p><p><strong><em>Use aseptic technique!</em></strong></p><p>To prevent stopper-derived rubber particles from being administered with the medicinal product (risk of microembolism), use the enclosed filter set. To withdraw the dissolved preparation, fit the filter set onto the enclosed disposable syringe and insert it through the rubber stopper (fig. E).</p><p>Disconnect the syringe for a moment from the filter set. Air will enter into the powder vial and any foam will collapse. Then draw the solution into the syringe through the filter set (fig. F).</p><p>Disconnect the syringe from the filter set and slowly inject the solution intravenously (maximum rate of injection: 2 ml per minute) with the enclosed winged infusion set (or the enclosed disposable needle).</p><p><img src="data:image/png;base64,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" alt="" width="390" height="231" vspace="0" hspace="0" border="0" style="width:390px;height:231px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p>Any unused product or waste material should be disposed of in accordance with local requirements. The administration of Immunate should be documented, and the lot number recorded. A detachable documentation label is attached to each vial.</p><p><strong>Frequency of administration</strong></p><p>Your doctor will tell you how often and at what intervals Immunate is to be administered. He/she will do this according to the effectiveness in your individual case.</p><p><strong>&nbsp;</strong></p><p><strong>Duration of treatment</strong></p><p>Usually, the replacement therapy with Immunate is life-long treatment.</p><p><strong>If you use more Immunate than you should</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No symptoms of overdose with coagulation factor VIII have been reported. If you have any doubts, please consult your doctor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thromboembolic events may occur.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hemolysis may occur in patients with blood group A, B, or AB.</p><p><strong>If you forget to use Immunate</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take a double dose to make up for a forgotten dose.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proceed with the next regular administration immediately and continue at regular intervals as advised by your doctor.</p><p><strong>If you stop using Immunate</strong></p><p>Do not make a decision to stop using Immunate without consulting your doctor.</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Serious side effects possible with human plasma derived factor VIII products</p><p>Allergic reactions, which may in some cases progress to severe and potentially life-threatening reactions (anaphylaxis), have been observed rarely. Therefore you should be aware of the early signs of allergic reactions such as flush, rash, hives, wheals, generalised itching, swelling of lips and tongue, dyspnoea (difficulty in breathing), wheezing (impaired breathing in and/or out due to constriction of the air passages), tightness in the chest, low blood pressure, drop in blood pressure, general feeling of being unwell, and dizziness. These symptoms may be early signs of an anaphylactic shock. If allergic or anaphylactic reactions occur, <u>stop the injection/infusion immediately and inform your doctor. </u>Severe symptoms require immediate emergency treatment.</p><p>For children not previously treated with Factor VIII medicines, inhibitor antibodies (see section 2) may form very commonly (more than 1 in 10 patients); however patients who have received previous treatment with Factor VIII (more than 150 days of treatment) the risk is uncommon (less than 1 in 100 patients). If this happens you or your child&acute;s medicines may stop working properly and you or your child may experience persistent bleeding. If this happens, you should contact your doctor immediately.</p><p>The formation of neutralising antibodies (inhibitors) to von Willebrand factor is a known complication in the treatment of patients with von Willebrand&rsquo;s disease. If you develop neutralising antibodies (inhibitors), this can manifest itself as an insufficient clinical response (bleeding is not controlled with an appropriate dose) or as allergic reaction. In these cases, it is recommended to contact a specialised haemophilia centre.</p><p>If you have blood group A, B or AB, haemolysis may occur following the administration of large doses.</p><p>Side effects reported with the use of Immunate</p><p><strong><em>Very common (may affect more than 1 in 10 people)</em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Factor VIII inhibition (for children not previously treated with Factor VIII medicines).</p><p><strong><em>Uncommon (may affect up to 1 in 100 people)</em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Factor VIII inhibition (for patients who have received previous treatment with Factor VIII (more than 150 days of treatment)).</p><p><strong><em>Not known (frequency cannot be estimated from the available data)</em></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coagulopathy (inability to form clots)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Restlessness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paraesthesia (tingling or pricking sensation)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Conjunctivitis (pink eye)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia (rapid heartbeat)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations (feeling one&rsquo;s heartbeat)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension (low blood pressure)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushing</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pallor (Pale appearance)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dyspnoea (shortness of breath)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urticaria (nettle rash on the entire body)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritus (itching sensation)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erythema (redness of the skin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperhidrosis (excessive sweating)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neurodermatitis (itchy or scratchy skin)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Myalgia (muscle pain)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest discomfort</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema (fluid retention)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrexia (fever)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Burning and stinging at the injection site injections site reactions</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the following national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&minus; <em>To reports any side effect(s):</em></p><p>&bull;&nbsp; <strong><em>Saudi Arabia:</em></strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:533px"><tbody><tr><td style="vertical-align:top"><p>&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&bull;&nbsp; <strong><em>Other GCC States:</em></strong></p><p>- Please contact the relevant competent authority.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Store and transport refrigerated (2&deg;C-8&deg;C). Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.</p><p>During the shelf life the product may be kept at room temperature (up to 25&deg;C) for a single period not exceeding 6 months. Please record the beginning of storage at room temperature on the product carton. After storage at room temperature, Immunate must not be put back into the refrigerator but is to be used immediately or to be discarded.</p><p>Do not use this medicine if you notice that the reconstituted product solution is turbid or has deposits.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Powder</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are human coagulation factor VIII and human von Willebrand factor. Each vial nominally contains 1000 IU human coagulation factor VIII and 750 IU human plasma derived von Willebrand factor.</p><p>After reconstitution with the supplied solvent, the product contains approximately 100 IU/ml human plasma derived coagulation factor VIII and 75 IU/ml human plasma derived von Willebrand factor.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are human albumin, glycine, sodium chloride, sodium citrate, lysine hydrochloride and calcium chloride.</p><p>Solvent</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sterilised water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Powder and solvent for solution for injection.
White or pale yellow powder or friable solid.
Both powder and solvent come in single dose glass vials, EP (powder: hydrolytic type II; solvent: hydrolytic type I) closed by butyl rubber stoppers, EP.


Each pack contains:
1 vial of Immunate 1000 IU FVIII/750 IU VWF
1 vial with Sterilised Water for Injections (10 ml)
1 transfer/filter set
1 disposable syringe (10 ml)
1 disposable needle
1 winged infusion set
Pack size: 1 x 1000 IU FVIII/750 IU VWF



            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer<br />Takeda Manufacturing Austria AG<br />Industriestrasse 67<br />1221 Vienna, Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in May 2023 driven from EU SmPC approved on 09 February 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>التعريف بدواء إمیونیت</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إمیونیت هو مركب من عامل التخثر الثامن/ عامل فون ويلبراند مصنوع من البلازما البشرية. ويحل عامل التخثر الثامن في إمیونیت محل العامل الثامن الناقص أو الذي لا يعمل على نحو صحيح في هيموفيليا أ. وهيموفيليا أ هي عيب تخثر الدم الوراثي المرتبط بالجنس الناجم عن انخفاض مستويات العامل الثامن. ويؤدي هذا إلى حدوث نزيف حاد في المفاصل والعضلات والأعضاء الداخلية، إما تلقائيًا أو نتيجة صدمة عرضية أو جراحية. ويعوض إمیونیت نقص العامل الثامن مؤقتًا ويقلل من قابلية النزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وبالإضافة إلى كونه بروتينًا حاميًا للعامل الثامن، فإن عامل فون ويلبراند يحفز التصاق الصفائح الدموية بأماكن الجروح في الأوعية الدموية ويؤدي دورًا في تكدس الصفائح الدموية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>فيمَ يُستخدم إمیونیت</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم إمیونیت لعلاج النزيف في حالات هيموفيليا أ الخلقية و الوقاية منه، أو في حالات نقص العامل الثامن المكتسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم إمیونیت أيضًا لعلاج النزيف لدى المرضى المصابين بمرض فون ويلبراند مع نقص العامل الثامن، وإن لم يتوفر علاج مخصص فعّال ضد مرض فون ويلبراند، وعندما يكون علاج ديزموبريسين وحده غير فعّال أو محظور استعماله.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم إمیونیت</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت مصابًا بحساسية تجاه عامل التخثر البشري الثامن أو أيٍ من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كنت غير متأكد من هذا، فاسأل طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عند حدوث تفاعلات الحساسية:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هناك فرصة نادرة لأن تتعرض لصدمة الحساسية (رد فعل تحسسي عنيف ومفاجئ) تجاه إمیونیت. ويجب أن تكون على دراية بالعلامات المبكرة للتفاعلات التحسسية مثل الاحمرار، والطفح الجلدي، والشرى، والانتبارات، والحكة الشاملة، وتورم الشفتين والجفنين واللسان، وضيق التنفس، وأزيز الصدر وألمه وضيقه، والشعور العام بالتوعك، والدوخة، وتسارع نبضات القلب، وانخفاض ضغط الدم. يمكن أن تشكل هذه الأعراض بوادر حدوث صدمة الحساسية، التي قد تشمل مظاهرها أيضًا الدوخة الشديدة وفقدان الوعي وصعوبة التنفس الشديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة ظهور أيٍ من هذه الأعراض، <u>فأوقف الحقن/ التسريب فورًا واتصل بطبيبك</u>. تتطلب الأعراض الشديدة، بما في ذلك صعوبة التنفس والإغماء (الموشك)، علاجًا طارئًا سريعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عندما تكون المتابعة ضرورية:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يرغب طبيبك في إجراء اختبارات للتأكد من أن جرعتك الحالية كافية للوصول إلى مستويات مناسبة من العامل الثامن أو عامل فون ويلبراند والحفاظ عليها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>عندما يستمر النزيف في الحدوث:</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُعد تكوين المثبطات (الأجسام المضادة) أحد المضاعفات المعروفة التي يمكن أن تحدث أثناء الخضوع للعلاج بجميع أدوية العامل الثامن. وتوقف هذه المثبطات، خاصة عند المستويات العالية، العلاج عن العمل على نحو صحيح وستخضع أنت أو طفلك لمتابعة تطور هذه المثبطات بعناية. وإن لم ينضبط نزيفك أو نزيف طفلك باستخدام إمیونیت، <u>فأخبر طبيبك على الفور</u>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إن كنت مصابًا بمرض فون ويلبراند، خاصة النوع 3، فقد تطوِّر أجسامًا مضادة محايدة (مثبطات) لعامل فون ويلبراند.</strong> قد يرغب طبيبك في إجراء اختبارات لتأكيد ذلك. ومثبطات عامل فون ويلبراند هي أجسام مضادة داخل الدم تحجب عامل فون ويلبراند الذي تستخدمه. ويجعل هذا عامل فون ويلبراند أقل فاعلية في السيطرة على النزيف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند تصنيع الأدوية من الدم أو البلازما البشرية، توضع تدابير معينة لمنع انتقال العدوى إلى المرضى. ويشمل ذلك الاختيار الدقيق للمتبرعين بالدم والبلازما للتأكد من استبعاد الأشخاص المعرضين لنقل العدوى ، واختبار كل عينة تبرع وأحواض البلازما بحثًا عن علامات الفيروس/العدوى، وإدراج خطوات أثناء معالجة الدم أو البلازما من شأنها تعطيل الفيروسات أو إزالتها. وبالرغم من تطبيق هذه التدابير، عند إعطاء الأدوية المحضرة من الدم البشري أو البلازما البشرية، فلا يمكن استبعاد إمكانية انتقال العدوى بالكلية. وينطبق هذا أيضًا على أي فيروسات غير معروفة أو ناشئة أو أنواع أخرى من العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تُعد التدابير المتخذة فعّالة تجاه الفيروسات المغلّفة - مثل فيروس نقص المناعة البشرية وفيروس التهاب الكبد (ب) وفيروس التهاب الكبد (ج)- وتجاه فيروس التهاب الكبد (أ) غير المغلف. وقد تكون التدابير المتخذة ذات قيمة محدودة تجاه الفيروسات غير المغلفة مثل parvovirus B19 (البارفو). وقد تكون عدوى فيروس البارفو B19 خطيرة على النساء الحوامل (العدوى الجنينية)، وعلى الأفراد الذين يعانون من ضعف الجهاز المناعي، أو المصابين ببعض أنواع فقر الدم (مثل مرض الخلايا المنجلية أو فقر الدم الانحلالي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">وقد يوصي طبيبك بأن تفكر في أخذ تطعيم ضد التهاب الكبد (أ) و(ب) إن كنت تتلقى بانتظام/ على نحو متكرر منتجات العامل الثامن المشتقة من البلازما البشرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويوصى بشدة في كل مرة تتلقى جرعة من إمیونیت أن تعمد إلى تسجيل اسم الدواء ورقم الدفعة من أجل الاحتفاظ بسجل للدفعات المستخدمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويحتوي إمیونیت على أيزو أجليوتينين لفصيلة الدم (anti-A وanti-B). إن كنت تملك فصيلة دم A أو B أو AB، فقد يحدث انحلال للدم بعد تلقي العلاج على نحو متكرر خلال فترات قصيرة أو بعد تلقي جرعات كبيرة جدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استخدام المنتج بحذر في الأطفال الذين تقل أعمارهم عن 6 سنوات ممن لديهم تعرض محدود لمنتجات العامل الثامن ، إذ تُعد البيانات السريرية المتاحة في هذه المجموعة من المرضى محدودة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وإمیونیت</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلاني إن كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم ترد تقارير عن أي تفاعلات بين إمیونیت والمنتجات الطبية الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب الامتناع عن خلط إمیونیت بالمنتجات أو المذيبات الطبية الأخرى -باستثناء الماء المعقم المعد للحقن المرفق- قبل الإعطاء لأنه قد يضعف فاعلية المنتج وسلامته. ويُنصح بغسل القسطرة الوريدية المثبتة بمحلول مناسب -مثل المحلول الملحي الفسيولوجي- قبل تسريب إمیونیت الوريدي وبعده.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إمیونیت مع الطعام والشراب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوفر توصيات مخصوصة بشأن متى ينبغي إعطاء إمیونیت بالتزامن مع الوجبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوفر تجارب ذات صلة باستخدام إمیونیت أثناء الحمل والرضاعة الطبيعية وفترات الخصوبة، إذ إن مرض هيموفيليا أ نادر لدى النساء. ويجب استخدام إمیونیت أثناء الحمل والرضاعة إن ظهر داعٍ مؤكد له فقط. وإن كنتِ حاملاً أو مرضعًا، أو تعتقدين أنك قد تكونين حاملاً، أو تخططين لإنجاب طفل، فاستشيري طبيبك أو الصيدلاني قبل تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا توجد معلومات حول تأثير إمیونیت على القدرة على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إمیونیت يحتوي على الصوديوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على 19.6 ملجم من الصوديوم (المكون الرئيسي لملح الطعام/ المائدة) في كل قارورة. و هذا &nbsp;يعادل تقريبا 1% من الحد الأقصى اليومي الموصى به من الصوديوم للبالغين.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب أن تتلقى علاجك تحت إشراف طبيب ذي خبرة في علاج اضطرابات التحكم في النزف.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدم دائمًا هذا الدواء مثلما أخبرك طبيبك تمامًا. استشر طبيبك إن لم تكن متأكدًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">جرعة الوقاية من النزيف</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كنت تستخدم إمیونیت لمنع النزيف، <u>فسيحسب طبيبك الجرعة </u>لك. وسيفعل/ستفعل ذلك وفقًا لاحتياجاتك الخاصة. وستكون الجرعة المعتادة بين 20 إلى 40 وحدة دولية من العامل الثامن لكل كجم من وزن الجسم، تعطى كل منها بعد فترة يومين إلى 3 أيام. ومع ذلك، في بعض الحالات خاصة في المرضى الأصغر سنًا، قد يكون من الضروري تقليل الفترة بين الجرعات أو إعطاء جرعات أكبر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كنتَ تعتقد أن تأثير إمیونیت غير كافٍ، فاستشِر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">جرعة علاج النزيف</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كنت تتلقى إمیونیت لعلاج النزيف، <u>فسيحسب طبيبك الجرعة</u> لك. سيفعل/ستفعل ذلك وفقًا لاحتياجاتك الخاصة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كنت تعتقد أن تأثير إمیونیت غير كافٍ، فاستشر طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المتابعة على يد طبيبك</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيجري طبيبك الاختبارات المعملية المناسبة للتأكد من امتلاكك مستويات كافية من العامل الثامن. يعد هذا مهمًا خصوصًا إن كنت ستخضع لإجراء جراحة كبيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة في مرض فون ويلبراند</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يتحكم طبيبك في النزيف باتباع الإرشادات المعطاة لهيموفيليا أ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وسيلة الإعطاء و/أو كيفيته</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُعطى إمیونیت <u>داخل الوريد (في الوريد)</u> بعد تحضير المحلول بالمذيب المرفق.</p><p dir="RTL">&nbsp;</p><p dir="RTL">اتبع التعليمات المقدمة من طبيبك بدقة.</p><p dir="RTL">للإذابة، استخدم فقط مجموعة الإعطاء المتوفرة في العبوة لأن فشل العلاج يمكن أن يحدث نتيجة امتزاز عامل التخثر البشري الثامن على الأسطح الداخلية لبعض معدات التسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب حل إمیونیت قبل الإعطاء مباشرة. يجب استخدام المحلول بعد ذلك على الفور لأنه لا يحتوي على مواد حافظة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذابة المسحوق لإعداد محلول الحقن</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدم تقنية معقمة!</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دفئ القارورة غير المفتوحة التي تحتوي على المذيب (الماء المعقم للحقن) لتكون بدرجة حرارة الغرفة (بحد أقصى 37&deg;م).</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزل الغطاءين الواقيين عن قارورة المسحوق وقارورة المذيب (الشكل. أ) ونظف السدادات المطاطية لكلتيهما.</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع الحافة المتموجة لمجموعة النقل على قارورة المذيب واضغط عليها (الشكل. ب).</p><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزل الغطاء الواقي عن الطرف الآخر لمجموعة النقل مع الحرص على عدم لمس الطرف المكشوف.</p><p dir="RTL">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اقلب مجموعة النقل مع قارورة المذيب الموصولة فوق قارورة المسحوق، وأدخل الإبرة الحرة عبر السدادة المطاطية لقارورة المسحوق (الشكل. ج). سوف يُسحب المذيب داخل قارورة المسحوق بالتفريغ.</p><p dir="RTL">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد مرور قرابة الدقيقة الواحدة، افصل القارورتين بإزالة مجموعة النقل مع قارورة المذيب الموصولة عن قارورة المسحوق (الشكل. د). ونظرًا لأن المستحضر يذوب بسهولة، حرك قارورة المُركَّز بلطف فقط -إن وجب عليك ذلك. ولا تهز محتويات القارورة. ولا تقلب قارورة المسحوق حتى تكون جاهزًا لسحب المحتويات.</p><p dir="RTL">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد الإذابة، يجب فحص المحلول المحضر بصريًا للتأكد من عدم وجود جسميات دقيقة أو تغير في لونه قبل إعطائه. يجب أن يكون المحلول رائقًا إلى براق بعض الشيء. مع ذلك، حتى عند اتباع إجراءات الإذابة بدقة، قد تكون بعض الجسيمات الصغيرة مرئية في بعض الأحيان. سوف تزيل مجموعة الفلتر المرفقة الجسيمات ولن تنخفض الفاعلية الموصوفة. يجب التخلص من المحاليل العكرة أو التي تحتوي على رواسب. يجب عدم وضع المحلول الجاهز للاستخدام في الثلاجة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">طريقة إعطاء الدواء</p><p dir="RTL">&nbsp;</p><p dir="RTL">استخدم تقنية معقمة!</p><p dir="RTL">&nbsp;</p><p dir="RTL">من أجل منع إعطاء جزيئات المطاط الخارجة من السدادة مع المنتج الطبي (خطر حدوث الانصمام الدقيق)، استخدم مجموعة الفلتر المرفقة. لسحب المستحضر المذاب، ركّب الفلتر فوق المحقنة ذات الاستعمال الواحد المرفقة وأدخلها عبر السدادة المطاطية (الشكل. هـ).</p><p dir="RTL">افصل المحقنة للحظة عن مجموعة الفلتر. سوف يدخل الهواء في قارورة المسحوق وتنكمش أي رغوة. ثم اسحب بعدها المحلول في المحقنة عبر مجموعة الفلتر (الشكل. و).</p><p dir="RTL">افصل المحقنة عن مجموعة الفلتر واحقن المحلول ببطء داخل الوريد (الحد الأقصى لمعدل الحقن: 2 مل في الدقيقة) باستخدام مجموعة التسريب المجنحة المرفقة (أو الإبرة ذات الاستعمال الواحد المرفقة).</p><p dir="RTL"><img src="data:image/png;base64,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" alt="" width="428" height="228" vspace="0" hspace="0" border="0" style="width:428px;height:228px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p dir="RTL">يجب التخلص من أي منتج أو نفايات غير مستخدمة وفقًا للمتطلبات المحلية.</p><p dir="RTL">يجب أن يكون إعطاء إمیونیت موثقًا، ورقم الدفعة مسجلًا. يرفق ملصق توثيق قابل للفصل بكل قارورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تواتر الإعطاء</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يخبرك طبيبك بعدد مرات تلقي إمیونیت وطول الفترة بين الجرعات. سيفعل/ ستفعل ذلك تبعًا لفاعليته حسب حالتك الفردية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدة العلاج</p><p dir="RTL">&nbsp;</p><p dir="RTL">عادة، ما يكون العلاج التعويضي بإمیونیت طيلة الحياة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن استخدمت إمیونیت أكثر مما ينبغي</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم ترد تقارير عن أي أعراض ناتجة عن تلقي جرعة زائدة من عامل التخثر الثامن. إن ساورتك أي شكوك، فيرجى استشارة الطبيب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تحدث حالات إصابة بالانصمام الخثاري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يحدث انحلال للدم في المرضى الذين يملكون فصيلة الدم A أو B أو AB.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن نسيت استخدام إمیونیت</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذ جرعة مزدوجة لتعويض الجرعة المنسية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلقَ الجرعة التالية فورًا وواصل على فترات منتظمة حسب إرشادات الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن توقفت عن استخدام إمیونیت</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخذ قرارًا بالتوقف عن استخدام إمیونیت دون استشارة طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن طرأت لك أي أسئلة أخرى حول استخدام هذا الدواء، فاطرحها على طبيبك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية على الرغم من أنها لا تصيب الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الآثار الجانبية الخطيرة المحتملة مع منتجات العامل الثامن المشتقة من البلازما البشرية</p><p dir="RTL">&nbsp;</p><p dir="RTL">ردود الفعل التحسسية -التي قد تتطور في بعض الحالات إلى ردود فعل شديدة ومهددة للحياة (صدمة الحساسية)- لوحظ حدوثها نادرًا. لذلك يجب أن تكون على دراية بالعلامات المبكرة لردود الفعل التحسسية مثل الاحمرار، والطفح الجلدي، والشرى، والانتبارات، والحكة الشاملة، وتورم الشفتين واللسان، وضيق التنفس (صعوبة التنفس)، وأزيز الصدر (قصور الشهيق و/ أو الزفير بسبب ضيق المجاري الهوائية)، وضيق الصدر، وانخفاض ضغط الدم، والشعور العام بالتوعك، والدوخة. يمكن أن تشكل هذه الأعراض بوادر حدوث صدمة الحساسية. في حالة حدوث تفاعلات تحسسية أو تأقية، <u>فأوقف الحقن/ التسريب على الفور وأخبر طبيبك.</u> تتطلب الأعراض الشديدة علاجًا طارئًا فوريًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأطفال الذين لم يسبق لهم العلاج بأدوية العامل الثامن، قد يشيع جدًا تكوين الأجسام المضادة المثبطة (انظر القسم 2) (لدى ما يفوق مريض واحد من كل 10 مرضى)؛ ومع ذلك، في المرضى الذين تلقوا علاجًا سابقًا بالعامل الثامن (لأكثر من 150 يومًا من العلاج) يكون الخطر غير شائع (أقل من مريض واحد لكل 100). إن حدث هذا، فقد تتوقف أدويتك أو أدوية طفلك عن العمل على نحو صحيح وقد تعاني أنت أو طفلك من نزيف مستمر. إن حدث هذا، فيجب عليك الاتصال بطبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يعد تكوين الأجسام المضادة المحيِّدة (المثبطات) لعامل فون ويلبراند ضمن المضاعفات المعروفة في علاج المرضى المصابين بمرض فون ويلبراند. إن طورت أجسامًا مضادة محيدة (مثبطات)، فقد يظهر ذلك في صورة استجابة سريرية غير كافية (لا يمكن التحكم في النزيف بتلقي الجرعة المناسبة) أو في صورة تفاعل تحسسي. في هذه الحالات، يوصى بالتواصل مع مركز متخصص في الهيموفيليا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إن كنت تملك فصيلة دم A أو B أو AB، فقد يحدث انحلال للدم بعد إعطاء جرعات كبيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المبلغ عنها أثناء استخدام </strong><strong>إمیونیت</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا (قد تصيب أكثر من 1 من كل 10 أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثبيط العامل الثامن (في الأطفال الذين لم يسبق لهم العلاج بأدوية العامل الثامن).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تصيب ما يصل إلى 1 من كل 100 شخص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تثبيط العامل الثامن (في المرضى الذين تلقوا علاجًا سابقًا بالعامل الثامن (أكثر من 150 يومًا من العلاج)).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير معدل تواترها من البيانات المتاحة)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاعتلال التخثري (العجز عن تكوين الجلطات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التململ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالخدر (التنميل أو الوخز)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الملتحمة (العين الوردية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع نبض القلب (ضربات القلب السريعة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان (الشعور بنبض القلب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاحمرار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشحوب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس (صعوبة التنفس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأرتيكاريا (طفح القراص على كامل الجسم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمامي (احمرار الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط التعرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد العصبي (حكة الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم العضلي (وجع العضلات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بعدم الراحة في الصدر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التورم (احتباس السوائل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة (الحمى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الارتجاف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالحرقة واللدغ في موضع الحقن (تفاعلات موضع الحقن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الألم</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إن أصبت بأي آثار جانبية، فتحدث إلى طبيبك. يشمل هذا أي آثار جانبية محتملة غير مدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الآثار الجانبية مباشرة عبر اتباع نظام الإبلاغ الوطني. بالإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp; <strong>&nbsp;المملكة العربية السعودية:</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:533px"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&minus; المركز الوطني للتيقظ الدوائي وسلامة الأدوية</p><p dir="RTL">o مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">o البريد الإلكتروني: npc.drug@sfda.gov.sa o الموقع الإلكتروني: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp; </strong><strong>دول مجلس التعاون الخليجي الأخرى:</strong></p><p dir="RTL">- يرجى الاتصال بالسلطة المختصة ذات الصلة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن أنظار الأطفال ومتناولهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ ويُنقل داخل الثلاجة (2&deg;م-8&deg;م). لا تجمده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في علبته الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المدون على الملصق والعبوة الكرتونية بعد الرمز EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء فترة الصلاحية، يمكن الاحتفاظ بالمنتج في درجة حرارة الغرفة (حتى 25&deg;م) لفترة واحدة لا تتجاوز 6 أشهر. يرجى تسجيل بداية التخزين في درجة حرارة الغرفة على العبوة الكرتونية للمنتج. بعد تخزينه في درجة حرارة الغرفة، يجب عدم إعادة إمیونیت إلى الثلاجة، بل يجب استخدامه على الفور أو التخلص منه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إن لاحظت أن محلول المنتج المعاد تركيبه عكر أو يحتوي على رواسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أي دواء في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلاني عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المسحوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعّالة هي عامل التخثر البشري الثامن وعامل فون ويلبراند البشري. تحتوي كل قارورة نظريًا على 1000 وحدة دولية من عامل التخثر البشري الثامن و750 وحدة دولية من عامل فون ويلبراند المشتق من البلازما البشرية. بعد الإذابة باستخدام المذيب المرفق، يحتوي المنتج على ما يقارب 100 وحدة دولية/ مل من عامل التخثر الثامن المشتق من البلازما البشرية و75 وحدة دولية/ مل من عامل فون ويلبراند المشتق من البلازما البشرية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي الألبومين البشري، والجلايسين، وكلوريد الصوديوم، وسترات الصوديوم، وهيدروكلوريد الليسين، وكلوريد الكالسيوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المذيب</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مياه معقمة للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مسحوق ومذيب للمحلول لأجل الحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مسحوق أبيض أو أصفر شاحب أو صلب قابل للتفتيت.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يأتي كل من المسحوق والمذيب في قوارير زجاجية أحادية الجرعة، EP (المسحوق: التحلل المائي من النوع الثاني؛ المذيب: التحلل المائي من النوع الأول) مغلقة بسدادات مطاط البوتيل، EP.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على:</p><p dir="RTL">&nbsp;</p><p dir="RTL">قارورة واحدة من إمیونیت 1000 وحدة دولية من العامل الثامن/ 750 وحدة دولية من عامل فون ويلبراند</p><p dir="RTL">قارورة واحدة من الماء المعقم للحقن (10 مل)</p><p dir="RTL">مجموعة نقل/ فلتر واحدة</p><p dir="RTL">محقنة للاستعمال لمرة واحدة (10 مل)</p><p dir="RTL">إبرة للاستعمال لمرة واحدة</p><p dir="RTL">مجموعة حقن مجنحة واحدة</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العبوة: 1 &times; 1000 وحدة دولية من العامل الثامن/ 750 وحدة دولية من عامل فون ويلبراند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">Takeda Manufacturing Austria AG</p><p dir="RTL">Industriestrasse 67</p><p dir="RTL">1221 فيينا</p><p dir="RTL">النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            روجعت هذه النشرة لآخر مرة في مايو 2023 باتباع توجيهات ملخص خصائص المنتج للاتحاد الأوروبي المعتمد في 09 فبراير 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Immunate 1000 IU FVIII/750 IU VWF powder and solvent for solution for injection 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active Substances: Human coagulation Factor VIII/ Human von Willebrand Factor 
1 
Each vial contains nominally 1000 IU human coagulation factor VIII	and 750 IU human von 
2 
Willebrand factor	(VWF:RCo).
Immunate 1000 IU FVIII/750 IU VWF contains approximately 100 IU/ml of human coagulation factor VIII and 75 IU/ml human von Willebrand factor after reconstitution. 
The potency of factor VIII (IU) is determined using the European Pharmacopoeia chromogenic assay. 
3
The specific activity of Immunate is 70 ± 30 IU FVIII/mg protein . The potency of VWF (IU) is determined using the European Pharmacopoeia ristocetin co-factor assay (VWF:RCo). 
Produced from the plasma of human donors. 
Excipient(s) with known effect Sodium (19.6 mg per vial). 
For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection. 
White or pale yellow powder or friable solid. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment and prophylaxis of bleeding in patients with congenital (haemophilia A) or acquired factor VIII deficiency.</p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_13991" o:spid="_x0000_s1026" style='width:2in;height:.6pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="18288,76" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Shape_x0020_19652" o:spid="_x0000_s1027" style='position:absolute;
  width:18288;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="1828800,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l1828800,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,1828800,9144"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]-->Treatment of bleeding in patients with von Willebrand&#39;s disease with factor VIII deficiency, if no specific preparation effective against von Willebrand&rsquo;s disease is available, and when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be under the supervision of a physician experienced in the treatment of haemostatic disorders.</p><p><u>Treatment monitoring</u></p><p>During the course of treatment, appropriate determination of factor VIII levels is advised to guide the dose to be administered and the frequency of repeated infusions. In the case of major surgical interventions in particular, precise monitoring of the substitution therapy by means of coagulation analysis (plasma factor VIII activity) is indispensable. Individual patients may vary in their response to factor VIII, demonstrating different half-lives and recoveries. Dose based on bodyweight may require adjustment in underweight or overweight patients.</p><p><u>Posology</u></p><p>Dosage in Haemophilia A <strong>&nbsp;</strong></p><p>The dose and duration of the substitution therapy depend on the severity of the factor VIII deficiency, on the location and extent of the bleeding and on the patient&#39;s clinical condition.</p><p>The number of units of factor VIII administered is expressed in International Units (IU), which are related to the current WHO standard for factor VIII products. Factor VIII activity in plasma is expressed either as a percentage (relative to normal human plasma) or in International Units (relative to an International Standard for factor VIII in plasma).</p><p>One International Unit (IU) of factor VIII activity is equivalent to that quantity of factor VIII in one ml of normal human plasma.</p><p>The calculation of the required dose of factor VIII is based on the empirical finding that 1 International Unit (IU) factor VIII per kg body weight raises the plasma factor VIII activity by approximately 2% of normal activity.&nbsp;</p><p>The required dose is determined using the following formula:</p><p><strong>Required units = body weight (kg) x desired factor VIII rise (%) x 0.5 </strong></p><p>The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case.</p><p><em>Haemorrhages and Surgery</em></p><p>In the case of the following haemorrhagic events, the factor VIII activity should not fall below the given plasma activity level (in % of normal or IU/dl) in the corresponding period.</p><p>&nbsp;</p><p>The following table can be used to guide dosing in bleeding episodes and surgery:</p><table border="0" cellspacing="0" cellpadding="0" style="width:613px"><tbody><tr><td style="vertical-align:top"><p><strong>Degree of haemorrhage /Type of surgical procedure</strong></p></td><td><p><strong>Factor VIII level required</strong></p><p><strong>(% of normal) (IU/dl)</strong></p></td><td style="vertical-align:top"><p><strong>Frequency of Doses (hours) / </strong></p><p><strong>Duration of Therapy (days)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Haemorrhage</strong></p><p>Early haemarthrosis, muscle bleeding or oral bleeding</p></td><td style="vertical-align:top"><p>20 - 40</p></td><td style="vertical-align:bottom"><p>Repeat every 12 to 24 hours. At least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>More extensive haemarthrosis, muscle bleeding or haematoma</p></td><td style="vertical-align:top"><p>30 - 60</p></td><td><p>Repeat infusion every 12 &ndash; 24 hours for 3 &ndash; 4 days or more until pain and acute disability are resolved&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Life threatening haemorrhages&nbsp;</p></td><td style="vertical-align:top"><p>60 - 100</p></td><td><p>Repeat infusion every 8 to 24 hours until threat is resolved</p></td></tr><tr><td><p><strong>Surgery</strong></p><p><em>Minor</em></p><p>Including tooth extraction</p></td><td style="vertical-align:bottom"><p>30 - 60</p></td><td style="vertical-align:bottom"><p>Every 24 hours, at least 1 day, until healing is achieved.</p></td></tr><tr><td style="vertical-align:top"><p><em>Major</em></p></td><td style="vertical-align:top"><p>80 &ndash; 100</p><p>(pre- and postoperative)</p></td><td><p>Repeat infusion every 8 &ndash; 24 hours until adequate wound healing, then therapy for at least another 7 days to maintain a factor VIII activity of 30 % to 60&nbsp;</p><p>% (IU/dl)</p></td></tr></tbody></table><p>Under certain circumstances (e.g. presence of a low titre inhibitor) doses larger than those calculated using the formula may be necessary.</p><p>Long-term prophylaxis</p><p>For long term prophylaxis against bleeding in patients with severe haemophilia A, the usual doses are 20 to 40 IU of factor VIII per kg body weight at intervals of 2 to 3 days. In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.</p><p>Dosage in von Willebrand&#39;s disease &nbsp;</p><p>Replacement therapy with Immunate to control haemorrhages follows the guidelines given for haemophilia A.</p><p>Since Immunate contains a relatively high amount of factor VIII in relation to vWF, the treating physician should be aware that continued treatment may cause an excessive rise in factor VIII:C, which can lead to an increased risk of thrombosis.</p><p><em>Paediatric population</em></p><p>The product should be used with caution in children less than 6 years of age, who have limited exposure to factor VIII products, as there are limited data available for this patient group.&nbsp;&nbsp;</p><p>Dosing in haemophilia A in children and adolescents aged &lt; 18 years old is based on body weight and is therefore generally based on the same guidelines as for adults. The amount and frequency of administration should always be oriented to the clinical effectiveness in the individual case. (see section 4.4).&nbsp; In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary. <u>Method of administration</u>&nbsp; Intravenous use.</p><p>Immunate should be administered slowly via intravenous route. The maximal rate of infusion should not exceed 2 ml per minute.</p><p>Precautions to be taken before handling or administering the medicinal product</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Traceability</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>Hypersensitivity</p><p>Allergic type hypersensitivity reactions are possible with Immunate. If symptoms of hypersensitivity occur, patients should be advised to discontinue use of the medicinal product immediately and contact their physician. Patients should be informed of the early signs of hypersensitivity reactions including hives, generalised urticaria, rash, flushing, pruritus, oedema (including face and eyelid oedema), tightness of the chest, wheezing, dyspnoea, chest pain, tachycardia, hypotension, and anaphylaxis up to allergic shock. In case of shock, standard medical treatment for shock should be implemented.</p><p>Inhibitors (Patients with Haemophilia A)</p><p>The formation of neutralising antibodies (inhibitors) to factor VIII is a known complication in the management of individuals with haemophilia A. These inhibitors are usually IgG immunoglobulins directed against the factor VIII procoagulant activity, which are quantified in Bethesda Units (BU) per ml of plasma using the modified assay. The risk of developing inhibitors is correlated to the severity of the disease as well as the exposure to factor VIII, this risk being highest within the first 50 exposure days but continues throughout life although the risk is uncommon.</p><p>The clinical relevance of inhibitor development will depend on the titre of the inhibitor, with low titre inhibitors which are transiently present or remain consistently low titre posing less of a risk of insufficient clinical response than high titre inhibitors.&nbsp;</p><p>In general, all patients treated with coagulation factor VIII products should be carefully monitored for the development of inhibitors by appropriate clinical observations and laboratory tests. If the expected factor VIII activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, testing for factor VIII inhibitor presence should be performed. In patients with high levels of inhibitor, factor VIII therapy may not be effective and other therapeutic options should be considered.</p><p>Management of such patients should be directed by physicians with experience in the care of haemophilia and factor VIII inhibitors.</p><p>Cardiovascular events</p><p>In patients with existing cardiovascular risk factors, substitution therapy with FVIII may increase the cardiovascular risk.</p><p>Inhibitors (Patients with von Willebrand&rsquo;s disease)</p><p>Patients with von Willebrand disease, especially type 3 patients, may develop neutralizing antibodies (inhibitors) to von Willebrand factor. If the expected VWF:RCo activity plasma levels are not attained, or if bleeding is not controlled with an appropriate dose, an appropriate assay should be performed to determine if a von Willebrand factor inhibitor is present. In patients with high levels of inhibitor, von Willebrand factor therapy may not be effective and other therapeutic options should be considered.</p><p>Thrombotic events</p><p>There is a risk of occurrence of thrombotic events, particularly in patients with known clinical or laboratory risk factors. Therefore, patients must be monitored for early signs of thrombosis. Prophylaxis against venous thromboembolism should be instituted, according to the current recommendations. Since Immunate contains a relatively high amount of factor VIII in relation to&nbsp; VWF, the treating physician should be aware that continued treatment may cause an excessive rise in FVIII:C. In patients receiving Immunate, plasma levels of FVIII:C should be monitored to avoid sustained excessive FVIII:C plasma levels, which may increase the risk of thrombotic events.</p><p>Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/removal of viruses. Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded. This also applies to unknown or emerging viruses and other pathogens.</p><p>The measures taken are considered effective for enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) and for the non-enveloped hepatitis A virus (HAV). The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e.g. haemolytic anaemia).</p><p>Appropriate vaccination (hepatitis A and B) should be considered for patients in regular / repeated receipt of human plasma-derived factor VIII products.</p><p>Immunate contains blood group isoagglutinins (anti-A and anti-B). In patients with blood group A, B, or AB, haemolysis may occur following repetitive administration at short intervals or following administration of very large doses.</p><p>Sodium content</p><p>This medicinal product contains 19.6 mg sodium per vial, equivalent to approximately 1% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>Paediatric Population</p><p>The product should be used with caution in children less than 6 years of age, who have limited exposure to factor VIII products, as there are limited clinical data available for this patient group.</p><p>The listed warnings and precautions apply both to adults and paediatric patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.5 Interaction with other medicinal products and other forms of interaction </strong>&nbsp;</p><p>No interaction studies have been performed with Immunate.</p><p>No interactions of human coagulation factor VIII products with other medicinal products have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Animal reproduction studies have not been conducted with factor VIII. Based on the rare occurrence of haemophilia A in women, experience regarding the use of factor VIII during pregnancy and breastfeeding is not available. Therefore, Immunate should be used during pregnancy and lactation only if clearly indicated.</p><p>See section 4.4 for information on parvovirus B19 infection.</p><p>The effects of Immunate on fertility have not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no information on the effects of Immunate on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Undesirable effects possible with human plasma derived factor VIII products:</u></strong></p><p>Summary of the safety profile</p><p>Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria, rash, headache, hives, pruritus, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, dyspnoea, tingling, vomiting, wheezing) have been observed rarely and may in some cases progress to severe anaphylaxis (including shock). Patients should be advised to contact their physician if these symptoms occur (see section 4.4).</p><p>Development of neutralising antibodies (inhibitors) may occur in patients with haemophilia A treated with factor VIII, including with Immunate. If such inhibitors occur, the condition will manifest itself as an insufficient clinical response. In such cases, it is recommended that a specialised haemophilia centre be contacted.</p><p>Patients with von Willebrand disease, especially type 3 patients, may very rarely develop neutralising antibodies (inhibitors) to von Willebrand factor. If such inhibitors occur, the condition will manifest itself as an inadequate clinical response. Such antibodies may occur in close association with anaphylactic reactions. Therefore, patients experiencing anaphylactic reaction should be evaluated for the presence of an inhibitor. In all such cases, it is recommended that a specialised haemophilia centre be contacted.&nbsp;</p><p>Haemolysis may occur following administration of large doses to patients with blood group A, B or AB.</p><p>For safety information with respect to transmissible agents, see section 4.4.</p><p><strong><u>Undesirable effects based on reports from clinical trials and on post-marketing experience for</u> <u>Immunate:</u></strong></p><p>Tabulated list of adverse reactions</p><p>The table presented below is according to the MedDRA system organ classification (SOC and Preferred Term Level).</p><p>Frequencies have been evaluated according to the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000</p><p>to &lt;1/1,000), very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="0" cellspacing="0" cellpadding="0" style="width:640px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA Standard System Organ </strong>&nbsp;</p><p><strong>Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders &nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>Uncommon<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Factor VIII inhibition</p></td><td style="vertical-align:top"><p>Uncommon (PTPs)<sup>2</sup></p><p>Very common (PUPs)<sup>2</sup></p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Coagulopathy</p></td><td><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Restlessness</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Dizziness</p></td><td><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Headache</p></td><td><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Palpitations</p></td><td><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Flushing &nbsp;</p></td><td><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pallor</p></td><td><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Cough</p></td><td><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Nausea</p></td><td><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash &nbsp;</p><p>(including erythematous and papular rash)</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pruritus</p></td><td><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Erythema</p></td><td><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Hyperhidrosis</p></td><td><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Neurodermatitis</p></td><td><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr></tbody></table><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_18703" o:spid="_x0000_s1026" style='width:2in;height:.6pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="18288,76" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA79HGaI8CAAAFBwAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzUVc1u2zAMvg/YOwi+t3ayrk2DugXW
bb0Ma9G0D8DKcmxMlgRJSZ09/Shacoy0G/Zzmg+yRJEfP4oUdXHVd5JthXWtVmU2Oy4yJhTXVavW
Zfb48PlokTHnQVUgtRJlthMuu7p8++YClmsLpmk5QwTlllBmjfdmmeeON6IDd6yNULhXa9uBx6Vd
55WFZ0TuZD4vitO8g1Zll3uoj+CBbWz7F1BS82+iuga1BYeQki+nkshR8n9HhqXa3lizMnc2MOdf
t3eWtVWZ4ckp6PCIsjxuRDVc5gdW6z1AX9su6Ou6Zj2h7MJIGKL3jKNwtpgvFgU64Lh3djqP27y5
fcWIN59+ZYZUBpc4mdCgaeDxk+hmi7PiXYrwxuqNYYPofwzWmSHSl0mcnZ++P0lhrhowgg2iFGYw
SQlN5i7Wwh+n8nx2chIyPeYE62nj/I3QVBKw/eI8OV5XaQZNmvFepakV3DNJxeNptDQ+jYVkwAe7
EHWYsudJTTVlRjzCZqe34kGTmj+oRuS435VqqjWWZ6pc1E0a6W8Ib6o5CT4ppf+gjPWOgL+pRldi
9IuTECed7Bg7CqenK1U4hnCpwJRZLcFTK+paLyyTbYdHND8r8NYNCZKK0FKufb+iIvL9B13twok9
4R9bAfZSf4tDLTXCc9majDXafj+QUVql8yu/k4IWBCdUdQcW7hFIQmjBQh09riIF1MAY9h43TqzM
PeZ+YJgouQAZGEl1L2rsTdRWgsDZ9dO1RI4QioU+ihmkaSBKo6+oSh4JJ9jXrZQj5IxMX4Mc6ETl
YCfqGlmOlsVgySOboVgxVsxFKlmMczQiz1rt7RW+RInmECuqhzuNv9jH8oMHIO7RgxVemen68gcA
AAD//wMAUEsDBBQABgAIAAAAIQAJctEvHwcAAEcgAAAaAAAAY2xpcGJvYXJkL3RoZW1lL3RoZW1l
MS54bWzsWUtvGzcQvhfofyD23liSLVkyIgd+yHETvxApKXKkJGqXMXe5ICk7uhXJqZcCBdKihwbo
rYeiaIAGaNBLf4wBB236IzrkPkRKVPxAUASFYyDYnf1m+O3M7MyIvH3naczQCRGS8qQdVG9VAkSS
AR/SJGwHD3s7nzUDJBVOhpjxhLSDCZHBnfVPP7mN1waMpn2OxbAXkZggMJTINdwOIqXStaUlOQAx
lrd4ShJ4NuIixgpuRbg0FPgUFojZUq1SaSzFmCbBOlhU2lCHwX+JklowYKKrzRCU4BhWPxyN6IAY
7PC4qhFyIreYQCeYtQOwOeSnPfJUBYhhqeBBO6iYf8HS+u0lvJYrMbVA19LbMf9yvVxheFwza4qw
Xy5a6dSaK9XSvgEwNY/rNPVfac8A8GAAb5pxsW1W641Ks5ZjLVB26bHdWq0uu3jL/vIc52qrsVlb
cewbUGZ/ZQ5f2Wl1tusO3oAyfH0Ov1GpbbaWHbwBZfjGHH6ls7Fa6zh4A4oYTY7n0Y3VZrORo0vI
iLNdL7zVaFRWt3P4FAXZUGaXXmLEE7Uo12L8hIsdAGggw4omSE1SMsIDyMmNVHGJtqlMGZ4EKMUJ
lyCu1KpVSL2VSq38Mx7HawRb2poXMJFzIs0HyYGgqWoH98BqYEHO37w5e/b67NnvZ8+fnz37Fe3R
MFKZKUdvFyehrffup2/+efkl+vu3H9+9+NaPlzb+7S9fvf3jz/eZh09t6orz7169ff3q/Puv//r5
hcf6hsB9G96jMZHogJyiBzyGFzSucPmTvriaRi/C1NbYSEKJE6xX8djvqMhBH0wwwx7cJnH9+EhA
qfEB746fOIS7kRgr6rF4P4od4D7nbJMLrxfu67UsN/fGSehfXIxt3AOMT3xrb+HEiXJnnEKNpT6T
WxFxaB4xnCgckoQopJ/xY0I8b/eYUsev+3QguOQjhR5TtImp1yU92neyaaq0S2OIy8RHEOLt+Gb/
EdrkzPfW2+TERcK3gZmHfI8wx4138Vjh2Geyh2NmO3wPq8hHsjsRAxvXkQoiHRLGUWdIpPTpHAp4
Xyvo9zFUN2/Y99kkdpFC0WOfzT3MuY3c5sdbEY5TH7ZLk8jGfi6PIUUxOuLKB9/n7hei7yEOOFkY
7keUOOG+uBo8hCpnU5omiH4yFp5Y3iXcyd/uhI0w8ZWaDRE7JXZDUG92bI5DJ7X3CGH4FA8JQQ8/
9zDY5Knj8ynpexFUlV3iS6x72M1VfZ8QSZAZbubr5B6VTsp2ScgX8NmfzBSeCU5iLBZZPoCo2z7v
9AV8jJ73PGSDYxt4QGHeg3zxOuVQgg0ruRdaPYqw08D0vfTn60Q48bvMNwbf5ROHxiW+S9AhV9aB
wm7rvNc3PcycBaYJ08MU7fnKLag44Z+q6OZq1MZevZH70U7DANORM/TENLlgAvrvJh+YL85/eOlJ
wQ8z7fgNO6XqinPOolKyOzPdLMLNzjRbXAzpxz/SbONxckSgi8zXq5uJ5maiCf73E82i7/lmjlk0
bdzMMQHMFzdzTL618mHmmOnoAlON3l7ItnnMpk+8cM9nRBnrqgkje9Js+0j4NTPcAaHWM3ubpNwD
TCO41G0OFnBwocBGBwmuvqAq6kY4hb2haqCNhDI3HUqUcglbRkbsta3xbBzv82G21Wn2lipZZ5VY
TeWVOmw6ZXLYplIZurGaCzU/s58KfA3b0GyzFgS07lVIWIu5JJY9JFYL4QUk9K7Zh2HR8rBoavNF
qOZcAdTKqMDPbQQ/0ttBfUUTgo1xOYDRfKjjlIW6iK4J5oeM9CJnOhkA24rZm8C+eRnplua68PX0
22WpdolIOyRMULK0ckkYz5gBT0bwIzjPTi29DI2rxro1DalDT7vCrAf5PaWx2nwfi+vGGvRmawNL
7ErBEnTaDhrLdUiZAU7bwQi2jOEyTiF3pP7FhVkIhy0DJbIP/jqVJRVSbWMZZQ43RScLT0wVEYjR
uB3o1y/DwBJTQwy3ag0KwkdLrgVl5WMjB0F3g0xGIzJQdtgtifZ0dgsVPqsV3qdG/fpgrcnHEO5u
NDxFfTYWDzCkWH21qh04pBJODqqZN4cUjsLKQjbNv5nGlBd/+yzK5FAmxyyNcN5R7GKewU0/KemY
u9IH1l3+zuBQyyV5I+yHusHaTnW6adm6Mg4Lu+7FStpzVtGc9kynquiu6a9izgpFG5jx5fWavMWq
cDHUNLvDZ6V7tuS2ilo3MyeUXQIcXvrveq3fojZdzKGmGc+XYV2zc6nbO4oXvIDaZZqEVfUbhdkZ
v5U9wrscCK/V+UFvNmtBNCrmSuNp37H2Pk5RP6y2Azhahq3Bp3AFh9MByGpaVtMyuIITZ2gX2TFx
O8gvCgk8zyQlZrmQLBeYlUKyUkjqhaReSBqFpBEgc54KZ/j6KDVAxXEp9LD8eDWfLdyz//V/AQAA
//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVs
cy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hF
QfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIo
LnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16
WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUB
AAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAA
IQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAA
IQDv0cZojwIAAAUHAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2lu
ZzEueG1sUEsBAi0AFAAGAAgAAAAhAAly0S8fBwAARyAAABoAAAAAAAAAAAAAAAAA7AQAAGNsaXBi
b2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAA
AAAAAAAAQwwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYA
AAAABQAFAGcBAABGDQAAAAA=
">
 <v:shape id="Shape_x0020_19654" o:spid="_x0000_s1027" style='position:absolute;
  width:18288;height:91;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="1828800,9144" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m,l1828800,r,9144l,9144,,e" fillcolor="black" stroked="f"
  strokeweight="0">
  <v:stroke miterlimit="83231f" joinstyle="miter"/>
  <v:path arrowok="t" textboxrect="0,0,1828800,9144"/>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="192" height="1" src="file:///C:/Users/gjy9478/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:2in;height:.6pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]-->&nbsp;</p><p>1</p><p>&nbsp;One hypersensitivity reaction in 329 infusions in one clinical trial in 5 patients.</p><p>2</p><p>&nbsp;Frequency is based on studies with all FVIII products which included patients with severe haemophilia A. PTPs = previously-treated patients, PUPs = previously-untreated patients.</p><table border="0" cellspacing="0" cellpadding="0" style="width:640px"><tbody><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Chest discomfort</p></td><td><p>Unknown</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema &nbsp;</p><p>(including peripheral, eyelid and face oedema)</p></td><td style="vertical-align:top"><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pyrexia</p></td><td><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Chills</p></td><td><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Injection site reactions (including burning)</p></td><td><p>Unknown</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Pain</p></td><td><p>Unknown</p></td></tr></tbody></table><p><strong>Reporting of suspected adverse reactions </strong></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed below:</p><p>&minus; <em>To reports any side effect(s):</em></p><p><strong><em>Saudi Arabia:</em></strong></p><p>&minus; The National Pharmacovigilance and Drug Safety Centre (NPC) o SFDA Call Center: 19999&nbsp; o E-mail: <u>npc.drug@sfda.gov.sa</u>&nbsp; o Website: www.sfda.gov.sa/npc</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Other GCC States:</em></strong></p><p>- Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported.</p><p>Thromboembolic events may occur. See section 4.4.</p><p>Hemolysis may occur in patients with blood group A, B, or AB. See section 4.4.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic Group: anti-haemorrhagics: von Willebrand factor and coagulation factor VIII in combination. ATC code: B02BD06.</p><p><u>Mechanism of action</u></p><p>The factor VIII/von Willebrand factor complex consists of two molecules (factor VIII and von Willebrand factor) with different physiological functions. When infused into a haemophiliac patient, factor VIII binds to von Willebrand factor in the patient`s circulation. Activated factor VIII acts as a cofactor for activated factor IX, accelerating the conversion of factor X to activated factor X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. Haemophilia A is a sex-linked hereditary disorder of blood coagulation due to decreased levels of factor VIII:C and results in profuse bleeding into joints, muscles and internal organs, either spontaneously or as a results of accidental or surgical trauma. By replacement therapy the plasma levels of factor VIII are increased, thereby enabling a temporary correction of the factor deficiency and correction of the bleeding tendencies.</p><p>In addition to its role as a factor VIII protecting protein, von Willebrand factor (VWF) mediates platelet adhesion to sites of vascular injury and plays a role in platelet aggregation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All pharmacokinetic parameters for Immunate were measured in subjects with severe Haemophilia A</p><p>(factor VIII level  1%). The analysis of plasma samples was conducted in a central laboratory using a chromogenic FVIII assay. The pharmacokinetic parameters derived from a crossover study of&nbsp;</p><p>Immunate in 18 previously treated patients older than 12 years of age are listed in the table below.</p><p>Summary of pharmacokinetic parameters for Immunate in 18 patients with severe Haemophilia A (Dose = 50 IU/kg):</p><table border="0" cellspacing="0" cellpadding="0" style="width:603px"><tbody><tr><td rowspan="2"><p><strong>Parameter</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mean</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>SD</strong></p></td><td style="vertical-align:top"><p><strong>Median</strong></p></td><td style="vertical-align:top"><p><strong>90% CI</strong></p></td></tr><tr><td style="vertical-align:top"><p>AUC<sub>0-</sub><sub> </sub>([IUxh]/mL)</p></td><td style="vertical-align:top"><p>12.2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3.1</p></td><td style="vertical-align:top"><p>12.4</p></td><td style="vertical-align:top"><p>11.1 to 13.2</p></td></tr><tr><td style="vertical-align:top"><p>C<sub>max </sub>(IU/mL)</p></td><td style="vertical-align:top"><p>1.0</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0.8 to 1.0</p></td></tr><tr><td style="vertical-align:top"><p>T<sub>max </sub>(h)</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3 to 0.3</p></td></tr><tr><td style="vertical-align:top"><p>Terminal Half-Life (h)</p></td><td style="vertical-align:top"><p>12.7</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3.2</p></td><td style="vertical-align:top"><p>12.2</p></td><td style="vertical-align:top"><p>10.8 to 15.3</p></td></tr><tr><td style="vertical-align:top"><p>Clearance (mL/h)</p></td><td style="vertical-align:top"><p>283</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>146</p></td><td style="vertical-align:top"><p>232</p></td><td style="vertical-align:top"><p>199 to 254</p></td></tr><tr><td style="vertical-align:top"><p>Mean residence time (h)</p></td><td style="vertical-align:top"><p>15.3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>3.6</p></td><td style="vertical-align:top"><p>15.3</p></td><td style="vertical-align:top"><p>12.1 to 17.2</p></td></tr><tr><td style="vertical-align:top"><p>V<sub>ss </sub>(mL)</p></td><td style="vertical-align:top"><p>4166</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2021</p></td><td style="vertical-align:top"><p>3613</p></td><td style="vertical-align:top"><p>2815 to 4034</p></td></tr><tr><td style="vertical-align:top"><p>Incremental Recovery</p><p>([IU/mL]/[IU/kg])</p></td><td style="vertical-align:bottom"><p>0.020</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>0.006</p></td><td style="vertical-align:bottom"><p>0.019</p></td><td style="vertical-align:bottom"><p>0.016 to 0.020</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human blood coagulation factor VIII contained in Immunate is a normal constituent of the human plasma and acts like the endogenous factor VIII.&nbsp;</p><p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, local tolerance and immunogenicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Powder</u></p><p>Human albumin</p><p>Glycine</p><p>Sodium chloride</p><p>Sodium citrate&nbsp;</p><p>Lysine hydrochloride&nbsp;</p><p>Calcium chloride&nbsp;</p><p><u>Solvent</u></p><p>Sterilised Water for Injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.</p><p>Only the provided infusion sets should be used because treatment failure can occur as a consequence of human coagulation factor VIII adsorption to the internal surfaces of some infusion equipment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years. 
Chemical and physical in-use stability has been demonstrated for 3 hours at room temperature. From a microbiological point of view, unless the method of reconstitution precludes the risk of microbial contamination (controlled and validated aseptic conditions), the product should be used immediately.  
If not used immediately, in-use storage times and conditions are the responsibility of the user. Reconstituted product must not be returned to the refrigerator. 
During the shelf life, the product may be kept at room temperature (up to 25°C) for a single period not exceeding 6 months. Record the period of storage at room temperature on the product package. At the end of this period the product must not be returned to the refrigerator but should be used immediately or discarded. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store and transport refrigerated (2&deg;C-8&deg;C).&nbsp;</p><p>Do not freeze.</p><p>Store in original package in order to protect from light.&nbsp;</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Both powder and solvent come in single dose glass vials, EP (powder: hydrolytic type II; solvent: hydrolytic type I) closed by butyl rubber stoppers, EP.</p><p>1 vial of Immunate 1000 IU FVIII/750 IU VWF <em>&nbsp;</em></p><p>1 vial with Sterilised Water for Injections (10 ml)</p><p>1 transfer/filter set</p><p>1 disposable syringe (10 ml)</p><p>1 disposable needle</p><p>1 winged infusion set</p><p>Pack size: 1 x 1000 IU FVIII/750 IU VWF&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For reconstitution use only the administration set provided in the pack. Immunate is to be reconstituted immediately before administration as the preparation does not contain preservatives.&nbsp;</p><p>It is advisable to flush implanted venous access devices with isotonic saline prior to and after infusion of Immunate.&nbsp;</p><p><strong>Reconstitution of powder </strong>Use Aseptic Technique!</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Warm the unopened vial containing the solvent (Sterilised Water for Injections) to room temperature (maximum 37&deg;C).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove protective caps from the powder vial and solvent vial (fig. A) and cleanse the rubber stoppers of both.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place and press the undulated rim of the transfer set onto the solvent vial (fig. B).</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove protective covering from the other end of the transfer set taking care not to touch the exposed end.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Invert the transfer set with the attached solvent vial over the powder vial and insert the free needle through the rubber stopper of the powder vial (fig. C). The solvent will be drawn into the powder vial by vacuum.&nbsp;</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After approximately one minute, disconnect the two vials by removing the transfer set with the attached solvent vial from the powder vial (fig. D). Since the preparation dissolves easily, only&nbsp;</p><p>gently - if at all - agitate the concentrate vial. DO NOT SHAKE THE CONTENTS OF THE VIAL. DO NOT INVERT THE POWDER VIAL UNTIL READY TO WITHDRAW CONTENTS.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After reconstitution, the prepared solution should be inspected visually for particulate matter and discoloration prior to administration. The solution should be clear or slightly opalescent. However, even when the reconstitution procedure is strictly followed, a few small particles may occasionally be visible. The enclosed filter set will remove particles and the labelled potency will not be reduced. Solutions of reconstituted product that are turbid or have deposits must not be used.&nbsp;</p><p><strong>Administration </strong></p><p>Use Aseptic Technique!</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To prevent stopper-derived rubber particles from being administered with the medicinal product (risk of microembolism), use the enclosed filter set. To withdraw the dissolved preparation, fit the filter set onto the enclosed disposable syringe and insert it through the rubber stopper (fig. E).</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disconnect the syringe for a moment from the filter set. Air will enter into the powder vial and any foam will collapse. Then draw the solution into the syringe through the filter set (fig. F).&nbsp; 3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disconnect the syringe from the filter set and slowly inject the solution intravenously (maximum rate of injection: 2 ml per minute) with the enclosed winged infusion set (or the enclosed disposable needle).&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1680" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:261.75pt;height:130.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/gjy9478/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="349" height="174" src="file:///C:/Users/gjy9478/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" />&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fig. A fig. B &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fig. C &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fig. D &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fig. E &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fig. F</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Takeda Manufacturing Austria AG 
Industriestrasse 67 
A-1220 Vienna, Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2023 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>